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Resection of isolated metastases may contribute to
both symptom control and prolonged survival
even in the presence of widespread disease.
Case report
A 46-year-old premenopausal woman underwent
mastectomy and axillary clearance in 1993 for
multifocal right breast malignancy. Histology
demonstrated an 8 mm grade 1 carcinoma and
10 and 25 mm grade 3 carcinomas. There was no
nodal involvement. Hormone receptor status was
not assessed but she was prescribed adjuvant
tamoxifen for 5 years.
Almost 10 years later, in December 2002, our
patient underwent a left mastectomy and axillary
clearance for a 23 mm grade 3 invasive ductal car-
cinoma showing vascular invasion and involving
2 axillary lymph nodes. The carcinoma was only
focally ER positive and PR negative, but c-erbB2
strongly positive. She received adjuvant che-
motherapy [6 cycles FEC] and chest wall radio-
therapy, and in view of the albeit weak ER
positivity, she was started again on tamoxifen.
InAugust2004shecomplainedofbackpain.An
MRI scan demonstrated multiple bone metastases
in the cervical and thoracic spine, and there was
somespinalcordcompressionatT3.Agoodsymp-
tomatic response followed palliative radiotherapy
to the upper thoracic spine, and this was followed
by 6 cycles of docetaxel chemotherapy in combi-
nationwithtrastuzumab,achangeinherhormonal
treatmentfromtamoxifentoletrozole,and a2-year
course of bisphosphonate therapy with zoledronic
acid infusions. She continued indeﬁnitely on the
three weekly infusions of trastuzumab.
The response was maintained for 2 years, but
slight nausea and newly abnormal liver function
biochemistry led to a CT scan in August 2006.
This showed a 9 cm, apparently solitary, lower
right liver lobe metastasis in addition to the
numerous sclerotic bone metastases. There was
no clinical or investigative evidence of disease
progression at any site other than in the liver.
The liver metastasis was involving both the left
and right portal inﬂows and was considered
inoperable. It was decided to continue with trastu-
zumab but to treat again with docetaxel che-
motherapy. She received another 6 cycles and the
diameter of the metastasis reduced by more than
50%. It was then considered operable and follow-
ing an extended right hepatectomy in March
2007, she made an uneventful swift recovery.
Our patient remained symptomatically well
until November 2007, when her upper thoracic
spine again became painful. An MRI scan
showed some improvement in the degree of
bone involvement compared with the MRI scan
in 2004, but in view of the pain she was retreated
with palliative radiotherapy, to good effect. She
continued on trastuzumab and letrozole, and
remained symptomatically well until June 2008
when she developed headache, dizziness and
vomiting, and a CT scan showed an apparently
solitary 33 mm left cerebellar metastasis. She
underwent craniotomy and gross total resection.
This was followed by whole brain radiotherapy,
40 Gy in 20 fractions, and she made a good
recovery.
A now ‘routine’ 6-monthly whole body CTscan
in May 2010, showed a new 2.3 cm lesion in the
right adrenal gland. PET CT demonstrated that
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1this was the only signiﬁcant source of uptake.
There was only mild residual activity in the bone
metastases and the brain and liver were clear.
Adrenalectomy was undertaken in June 2010, his-
tology conﬁrming a 30 × 20 mm metastasis of
poorly differentiated ductal carcinoma with mod-
erate ER and weak PR positivity.
Our patient continues on the trastuzumab and
letrozole combination she has now taken for over
six years and is currently [April 2011] symptoma-
tically very well and continuing to enjoy a good
quality of life, her metastatic bone disease remain-
ing quiescent. She will shortly be receiving her
110th trastuzumab infusion.
Discussion
Our patient has widespread metastatic breast
carcinoma. Systemic treatments, together with
palliative radiotherapy, have been effective in con-
trolling her metastatic bone disease for over six
years, but not effective in preventing the develop-
ment of isolated metastases involving liver, brain
and adrenal gland. Heterogeneity of metastatic
disease within an individual patient is well
recognized
1 as is differential response to systemic
treatments where, for example, soft tissue and
bone metastases from breast cancer are more
likely than visceral metastases to respond to hor-
monal drugs.
The ro ˆle of surgery in the management of
patients with distant metastases from breast
cancer is undergoing reappraisal and Pockaj et al.
have conducted acomprehensive review of the rel-
evant literature.
2 Traditionally the indications for
surgery in these patients have been restricted to
palliation, but there is accumulating evidence
that resection and sometimes repeated resection
of oligometastatic disease in liver, lung and brain
can be invaluable in helping to achieve prolonged
disease control in carefully selected patients, par-
ticularly as an adjunct to effective systemic treat-
ment. In more recent years there have been
reports of improved survival following both resec-
tion of distant oligometastatic disease and of the
primary tumour.
Palliative surgery has been deﬁned as surgery
to relieve symptoms.
3 In our patient, the brain
and probably the liver metastases were causing
symptoms but the adrenal metastasis was not.
As a result, 2 of the 3 operations our patient has
undergone in the past 5 years have been of symp-
tomatic beneﬁt, and there can be little doubt that
they have been successful in improving both
quality and quantity of life.
Our patient is remarkable in that she has under-
gone successful resection of progressing isolated
metastases involving three other organs, while
her metastatic bone disease has been kept under
control with drugs and radiotherapy. Our experi-
ence thus suggests a potential ro ˆle for surgery as
more than merely a palliative treatment for care-
fully selected patients with isolated but far from
solitary metastases. Much caution must however
be exercised before extrapolating from experience
with a single patient.
Our patient’s ﬁrst evidence of visceral involve-
ment was in the liver. The value of liver resection
for selected patients with metastatic breast cancer
is now well documented.
4–6The majority of these
patients had disease conﬁned to the liver,
although a small minority had bone metastases
as well. Our patient’s liver metastasis was initially
considered inoperable, but resection became feas-
ible afterchemotherapy induced shrinkage. Adam
et al’s series
5 is the largest, and most of their 85
patients had chemotherapy before resection.
Our patient’s second isolated metastasis was in
the brain. The value of surgery and whole brain
radiation for metastatic breast cancer involving
brain is also well documented,
7–9 but usually the
prognosis for these patients remains poor. Our
patient has had no further evidence of brain
disease almost three years following treatment
and it seems probable that the whole brain radio-
therapy has been a major factor in achieving this,
although useful penetration of trastuzumab
through a blood-brain barrier damaged by meta-
static disease or radiotherapy may have been con-
tributory. Trastuzumab is thought not to cross the
intact blood-brain barrier, explaining why brain
metastases are relatively common in patients
who are receiving, or have received, otherwise
successful treatment. There is now substantial evi-
dence to justify continuation of trastuzumab fol-
lowing treatment for brain metastases in patients
whose disease outside the CNS has continued to
respond.
10
Our patient’s third isolated metastasis was in
the adrenal gland, detected on a 6-monthly CT
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2scan intended primarily for reassessment of her
liver. Castillo et al.
11 documented their experience
of laparoscopic adrenalectomy for suspected inci-
dentally discovered isolated metastatic disease
involving adrenal glands. Metastatic disease in
the adrenal gland was conﬁrmed in 22 of their
32 patients, but only one of these had breast
cancer.
Several authors over the past decade have
described improved survival in patients with
distant metastatic disease following resection of
the primary breast cancer. Seven reports have
been summarized by Pockaj et al.
2 All the series
have however been retrospective and subject to
potential bias, and the ro ˆle of such surgery
remains controversial. If there is a real beneﬁt, it
is possibly explained by the eradication of the
source of new distant metastases.
Trastuzumab [Herceptin] is a recombinant
humanized monoclonal antibody, given intrave-
nously, that attaches to the HER2 receptor
protein on the surface of the cancer cell and
affects its growth. It has transformed the outlook
for the minority of patients who have HER2 posi-
tive breast cancer, in both adjuvant and palliative
settings.
The value of continuing trastuzumab in the
presence of progressive disease outside the
central nervous system is controversial, although
improved time to further progression and overall
survival was demonstrated in a phase III random-
ized controlled study.
12 Current National Institute
for Health and Clinical Excellence guidelines
13
recommend discontinuation of trastuzumab
when there is disease progression outside the
central nervous system, but not if disease pro-
gression is within the central nervous system
alone. It seems likely that continuing both trastu-
zumab and the aromatase inhibitor letrozole has
played a very important part in achieving pro-
longed cancer control for our patient, particularly
in her bones, despite isolated progressive disease
elsewhere.
The improving medium to long term control of
metastatic breast cancer consequent on additional
effective systemic treatments seems likely to result
in an increasing ro ˆle for surgery, and presumably
also for stereotactic radiosurgery, for selected
patients with oligometastatic disease. Patients
with progressing isolated metastases may derive
more than merely palliative beneﬁt even in the
presence of disease at other sites, particularly if
the latter is stabilized by other treatments. While
at present there is no evidence to justify screening
investigations to detect other than local recurrence
in breast cancer patients on follow-up,
14 recent
and future developments in both drug and loca-
lized treatments might increase the chance of
beneﬁt from diagnosing oligometastatic disease
before it becomes symptomatic.
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